LOW-PV Continuation
Key claim: Italian LOW-PV responders continue long-term observational follow-up on ropeginterferon alfa-2b with retrospective and prospective data collection through March 2026.
Abstract
This multicenter longitudinal observational study focuses on Italian patients with Polycythemia Vera (PV) who were enrolled in the Low-PV RCT and continued receiving Ropeginterferon alfa-2b until the study’s conclusion on March 31, 2023. It includes patients who were responders to Ropeginterferon alfa-2b after two years in the phase II randomized trial “LOW-PV.” Data will be collected retrospectively every 6 months from March 31, 2023 to November 30, 2024 and prospectively from December 1, 2024 to March 31, 2026.
Why this matters
Italian LOW-PV responders continue long-term observational follow-up on ropeginterferon alfa-2b with retrospective and prospective data collection through March 2026.